Anya Burton1,2, Daniela Tataru2, Robert J Driver3, Thomas G Bird4,5,6, Dyfed Huws7, David Wallace8, Timothy J S Cross9, Ian A Rowe10,11, Graeme Alexander12, Aileen Marshall13. 1. HCC-UK/British Association for the Study of the Liver (BASL), Lichfield, UK. 2. National Cancer Registration and Analysis Service, National Disease Registration Service, Public Health England, London, UK. 3. Leeds Institute for Medical Research at St. James's, University of Leeds, Leeds, UK. 4. Cancer Research UK Beatson Institute, Glasgow, UK. 5. Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. 6. MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK. 7. Welsh Cancer Intelligence and Surveillance Unit, Knowledge Directorate, Public Health Wales, Cardiff, UK. 8. Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK. 9. Institute of Translational Medicine, The University of Liverpool, Liverpool, UK. 10. Leeds Institute for Medical Research, University of Leeds, Leeds, UK. 11. Leeds Liver Unit, St. James's University Hospital, Leeds, UK. 12. UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK. 13. Sheila Sherlock Liver Centre, The Royal Free Hospital, London, UK.
Abstract
BACKGROUND & AIMS: The incidence of primary liver cancer (PLC) is increasing in Western Europe. To understand trends over time and the current burden in the UK, a detailed analysis of the epidemiology of PLC and its subtypes was conducted. METHODS: Data on PLCs diagnosed during 1997-2017 were obtained from population-based, nationwide registries in the UK. European age-standardised incidence (ASR) and incidence-based mortality rates (ASMR) per 100,000 person-years were calculated overall and by sex and UK-nation. Annual percentage change in rates was estimated using Joinpoint regression. One-, 2-, and 5-year age-standardised net survival was estimated. RESULTS: A total of 82,024 PLCs were diagnosed. Both hepatocellular carcinoma (HCC) incidence and mortality rates trebled (ASR 1.8-5.5 per 100,000, ASMR 1.3-4.0). The rate of increase appeared to plateau around 2014/2015. Scottish men consistently had the highest HCC incidence rates. PLC survival increased, driven by a substantial increase in the proportion that are HCC (as prognosis is better than other PLCs) and in HCC survival (change in 1-year survival 24-47%). Intrahepatic cholangiocarcinoma was the most common PLC in women and 1-year survival improved from 22.6% to 30.5%. CONCLUSIONS: PLC incidence has been increasing rapidly but, as most risk factors are modifiable, it is largely a preventable cancer. This rate of increase has slowed in recent years, possibly attributable to effective treatment for hepatitis C. As other risk factors such as obesity and diabetes remain prevalent in the UK, it is unlikely the considerable burden of this disease will abate. While improvements in survival have been made, over half of patients are not alive after 1 year, therefore further progress in prevention, early detection, and treatment innovation are needed. LAY SUMMARY: Many more people are getting liver cancer, particularly the subtype hepatocellular carcinoma, than 20 years ago. Men in Scotland are most likely to get liver cancer and to die from it. Survival after liver cancer diagnosis is getting longer but still less than half are alive after 1 year. Crown
BACKGROUND & AIMS: The incidence of primary liver cancer (PLC) is increasing in Western Europe. To understand trends over time and the current burden in the UK, a detailed analysis of the epidemiology of PLC and its subtypes was conducted. METHODS: Data on PLCs diagnosed during 1997-2017 were obtained from population-based, nationwide registries in the UK. European age-standardised incidence (ASR) and incidence-based mortality rates (ASMR) per 100,000 person-years were calculated overall and by sex and UK-nation. Annual percentage change in rates was estimated using Joinpoint regression. One-, 2-, and 5-year age-standardised net survival was estimated. RESULTS: A total of 82,024 PLCs were diagnosed. Both hepatocellular carcinoma (HCC) incidence and mortality rates trebled (ASR 1.8-5.5 per 100,000, ASMR 1.3-4.0). The rate of increase appeared to plateau around 2014/2015. Scottish men consistently had the highest HCC incidence rates. PLC survival increased, driven by a substantial increase in the proportion that are HCC (as prognosis is better than other PLCs) and in HCC survival (change in 1-year survival 24-47%). Intrahepatic cholangiocarcinoma was the most common PLC in women and 1-year survival improved from 22.6% to 30.5%. CONCLUSIONS: PLC incidence has been increasing rapidly but, as most risk factors are modifiable, it is largely a preventable cancer. This rate of increase has slowed in recent years, possibly attributable to effective treatment for hepatitis C. As other risk factors such as obesity and diabetes remain prevalent in the UK, it is unlikely the considerable burden of this disease will abate. While improvements in survival have been made, over half of patients are not alive after 1 year, therefore further progress in prevention, early detection, and treatment innovation are needed. LAY SUMMARY: Many more people are getting liver cancer, particularly the subtype hepatocellular carcinoma, than 20 years ago. Men in Scotland are most likely to get liver cancer and to die from it. Survival after liver cancer diagnosis is getting longer but still less than half are alive after 1 year. Crown
Keywords:
AAPC, average annual percentage change; APC, annual percentage change; ASMR, age-standardised mortality rate; ASR, age-standardised incidence rate; BASL, British Association for the Study of the Liver; DAA, direct-acting antivirals; DCO, death certificate only; HCC, hepatocellular carcinoma HCV, hepatitis C virus; Hepatocellular carcinoma; ICCA, intrahepatic cholangiocarcinoma; ICD-10, International Classification of Diseases 10th Edition; ICD-O, International Classification of Diseases for Oncology; Incidence; Intrahepatic cholangiocarcinoma; Mortality; NAFLD, non-alcoholic fatty liver disease; NCRAS, National Cancer Registration and Analysis Service; NI, Northern Ireland; PLC, primary liver cancer; Primary liver cancer; Survival
Authors: John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores Journal: J Hepatol Date: 2014-03-27 Impact factor: 25.083
Authors: Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Katrina F Brown; Harriet Rumgay; Casey Dunlop; Margaret Ryan; Frances Quartly; Alison Cox; Andrew Deas; Lucy Elliss-Brookes; Anna Gavin; Luke Hounsome; Dyfed Huws; Nick Ormiston-Smith; Jon Shelton; Ceri White; D Max Parkin Journal: Br J Cancer Date: 2018-03-23 Impact factor: 7.640
Authors: Iain Macpherson; Kushala W M Abeysekera; Rebecca Harris; Dina Mansour; Stuart McPherson; Ian Rowe; William Rosenberg; John F Dillon; Andrew Yeoman Journal: Frontline Gastroenterol Date: 2022-01-24
Authors: Weiqi Liao; Peter Jepsen; Carol Coupland; Hamish Innes; Philippa C Matthews; Cori Campbell; Eleanor Barnes; Julia Hippisley-Cox Journal: Diagn Progn Res Date: 2022-10-20
Authors: Daniel Geh; Robyn Watson; Gourab Sen; Jeremy J French; John Hammond; Paul Turner; Tim Hoare; Kirsty Anderson; Michael McNeil; Stuart McPherson; Steven Masson; Jessica Dyson; Mhairi Donnelly; Louise MacDougal; Preya Patel; Mark Hudson; Quentin M Anstee; Steven White; Stuart Robinson; Sanjay Pandanaboyana; Lucy Walker; Misti McCain; Yvonne Bury; Shreya Raman; Alastair Burt; Daniel Parkinson; Beate Haugk; Antony Darne; Nick Wadd; Syed Asghar; Lavanya Mariappan; Jane Margetts; Benjamin Stenberg; John Scott; Peter Littler; Derek M Manas; Helen L Reeves Journal: BMJ Open Gastroenterol Date: 2022-04